In Vivo CAR-T

In vivo CAR-T is the route in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学 where the CAR-T manufacturing process is moved from the laboratory into the patient. Instead of extracting immune cells, engineering them outside the body, and reinfusing them, an injectable gene-delivery tool modifies target immune cells inside the body so they become CAR-T cells.

The episode explains why big pharma interest is high: in vivo CAR-T could make a personalized cell therapy look more like a scalable drug, reducing time, logistics, and manufacturing cost. 刘诚 still treats it as early and technically risky. The central problems are cell specificity, because the tool should modify T cells rather than unrelated tissue cells, and dose control, because clinicians cannot directly count the final number of qualified CAR-T cells produced inside the patient.

vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 adds In Vivo mRNA CAR-T as a specific in vivo route using mRNA-LNP delivery. The source emphasizes a different tradeoff from E235: shorter mRNA expression may be a weakness for durable cancer killing, but it could be acceptable or useful for autoimmune settings where transient cell clearance is enough.

156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 keeps in vivo CAR-T as the convenience-oriented future route after TCEs pressure ex vivo CAR-T. The source’s emphasis is practical: if immune-cell redirection works, moving the engineering step inside the body could matter because ordinary CAR-T manufacturing remains slow, expensive, and logistically heavy.

Key Claims

• In vivo CAR-T is attractive because it could remove much of the Ex Vivo CAR-T Manufacturing cycle.
• It still uses the patient’s own immune cells, so its promise is not the same as Allogeneic CAR-T.
• The source says the route may reduce per-patient manufacturing cost by roughly an order of magnitude, but that estimate remains source-scoped.
• In vivo delivery changes the production route; it does not automatically solve cancers that current CAR-T Cell Therapy cannot treat.
• The route still has to solve Solid Tumor CAR-T Constraints, Tumor Microenvironment suppression, and Cytokine Release Syndrome safety.
• Vol.117 adds that mRNA-based in vivo delivery may trade manufacturing convenience for shorter persistence.
• Episode 156 adds that TCE competition strengthens the case for simpler immune-redirection delivery models, while not solving toxicity or dose-control problems.

Connections

• CAR-T Cell Therapy and Cancer Immune Recognition Problem - therapy logic being moved into an in-body manufacturing process.
• Ex Vivo CAR-T Manufacturing and Allogeneic CAR-T - alternative production and sourcing models.
• 刘诚 and Eureka Therapeutics - source viewpoint and company context.
• China Cell Therapy Regulatory Dual Track - regulatory context if in vivo cell therapy moves from clinical exploration to broad commercialization.
• In Vivo mRNA CAR-T and T-Cell Engagers - vol.117 combination-innovation and lower-cost immune-redirection context.